CS MEDICA A/S: Update on CBD activity research and future patent

CS MEDICA A/S (“CS MEDICA” or the “Firm”) announces that a person of two hypotheses on CBD exercise in the human body has properly been confirmed.

In CS MEDICA’s continuously study on the efficacy of cannabinoids from the hashish plant, the Business evaluates the latest market of CBD isolate (98{d589daddaa72454dba3eae1d85571f5c49413c31a8b21559e51d970df050cb0e} pure CBD) and sourced CBD Isolate, from different producers assembly their preliminary needs of top quality, and exploration the efficacy of the unique sourced CBD in the human entire body.

The Company thinks that the analysis on the efficacy of CBD and other cannabinoids is the crucial to the long term of the hashish enterprise for the firm and in common for the marketplace and in the conclude for the sufferers obtaining a products that holds superior efficacy and higher high-quality with number of-to-none facet effects.

CBD isolate investigation & pilot review
In the investigation of the distinction concerning the several CBD isolates tested in the pilot review, CS MEDICA discovered that the requirements of the CBD Isolate were similar, but when the CBD composition was analyzed on a micro degree, it was identified that the construction was not identical.

In even further scientific studies on the change among the normal CBD isolates it was found out that the generation procedure has an influence on the CBD action. The latest awareness of triggers in the organic CBD has been carried out in CS MEDICA’s PCT patent application (The Worldwide Patent System – masking 153 countries) a continuations of the patent application earlier submitted to DK.

Just one of the previous two hypotheses successfully demonstrated
CS MEDICA’s R&D department has continued the investigate and has carried out several research with each other with Foremost European Research Laboratories and Unique Laboratory Accredited for CBD research to detect the trigger in the purely natural CBD for getting active or inactive for the body. The business has now concluded successfully one of the two past hypotheses, and even more studies and test will be performed on the very last speculation. The Company expects to have performed the remaining exams in the course of spring of 2023.

Long term patent on energetic CBD
When these scientific tests and examination have been concluded and the hypothesis has been successfully verified, CS MEDICA will acquire a new patent application, which will be filed with the patent business office. As this know-how is centered on primary study, this patent is expected to impression the CBD market place on a world wide scale, as a result the Company aims to be acknowledged as a potent CBD analysis Business in the marketplace, with a technologies/know-how other Corporations can employ.

Details about the Main Scientific Officer (CSO) in CS MEDICA
The R&D office in CS MEDICA is led by CEO & CSO Lone Henriksen, a biochemist who retains a Bachelor of Engineering from the Technological University of Denmark (DTU) and a bachelor in promoting from Copenhagen Company College (CBS). Lone has much more than 20 decades of practical experience in the pharmaceutical business in products enhancement, acquiring, sales, R&D, and quality management. In her past perform, she was, amongst other folks, guiding the worldwide cooperation in between Brenntag and Astra Zeneca. On a administration degree, she has encounter with the subsequent:

R&D and QA together with customers & suppliers
Product Advancement with buyers and sellers in just Large Pharma, e.g., Novo, Astra Zeneca, Leo, Pharma Cosmos, Pitzer, etc.
Sourcing new producers with new niche products
Deal and value negotiations
Guaranteeing GMP & GDP in the benefit chain
Networking and corporation with world-wide CMOs and labs

For a lot more details about CS MEDICA, make sure you call:Lone Henriksen, CEO
Telephone: + (45) 71 20 30 47
Electronic mail: [email protected]
Web-site: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-primarily based MedTech corporation fully commited to strengthening people’s lives with products that make a change. We blend science, nature, and enthusiasm to produce innovative alternate options with higher efficacy and bioavailability to people. From autoimmune to strain therapies, we intention to renovate health care with much more successful treatment options.

We research, build, manufacture, commercialize and model more than-the-counter (OTC) merchandise underneath pharmaceutical laws. At present, 21 items with cannabidiol aimed at autoimmune and worry-similar conditions have been formulated. The initial solutions arrived at Danish retailers in 2020, and now 9 goods are offered on the European market place at extra than 500 factors of sale. One more 12 solutions will be released right before the conclusion of 2024, with 11 patent-pending products. The product or service line surpasses competing solutions on the industry by remaining located at the intersection of all-natural products, science, and cannabinoid technology while becoming registered below pharmaceutical legislation.

CS MEDICA was regarded before this calendar year as a business of Europe’s major 10 MedTech corporations at European Lifestars Awards as the organization equally Study & Acquire, Manufacture, Distribute and Manufacturer lifetime-supporting health care technologies. The added research and innovation to acquire cutting-edge CBD technologies permit us to lead in CBD professional medical developments.

https://information.cision.com/cs-medica-a-s/r/cs-medica-a-s–update-on-cbd-exercise-research-and-potential-patent,c3690896

https://information.cision.com/cs-medica-a-s/i/isolate-2,c3129910

https://information.cision.com/cs-medica-a-s/i/isolate-1,c3129911